## Lise M Bjerre

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8920876/publications.pdf

Version: 2024-02-01

516215 360668 1,335 41 16 35 h-index citations g-index papers 43 43 43 2229 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Systemic quinolones and risk of retinal detachment I: analysis of data from the US FDA adverse event reporting system. Expert Opinion on Drug Safety, 2022, 21, 269-276.	1.0	4
2	Promoting deceased organ and tissue donation registration in family physician waiting rooms (RegisterNow-1): a pragmatic stepped-wedge, cluster randomized controlled registry trial. BMC Medicine, 2022, 20, 75.	2.3	1
3	Systemic quinolones and risk of retinal detachment III: a nested case–control study using a US electronic health records database. European Journal of Clinical Pharmacology, 2022, , 1.	0.8	2
4	Systemic quinolones and risk of acute liver failure III: A nested case–control study using a US electronic health records database. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2307-2314.	1.4	4
5	The Health System Costs of Potentially Inappropriate Prescribing: A Population-Based, Retrospective Cohort Study Using Linked Health Administrative Databases in Ontario, Canada. PharmacoEconomics - Open, 2020, 4, 27-36.	0.9	22
6	Developing key performance indicators for prescription medication systems. PLoS ONE, 2019, 14, e0210794.	1.1	3
7	Continuation or deprescribing of proton pump inhibitors: A consult patient decision aid. Canadian Pharmacists Journal, 2019, 152, 18-22.	0.4	17
8	Patient Values and Preferences Surrounding Proton Pump Inhibitor Use: A Scoping Review. Patient, 2018, 11, 17-28.	1.1	26
9	Health Services Use during Transition from Pediatric to Adult Care for Inflammatory Bowel Disease: A Population-Based Study Using Health Administrative Data. Journal of Pediatrics, 2018, 203, 280-287.e4.	0.9	26
10	Comparative, cross-sectional study of the format, content and timing of medication safety letters issued in Canada, the USA and the UK. BMJ Open, 2018, 8, e020150.	0.8	10
11	Health system costs of potentially inappropriate prescribing in Ontario, Canada: a protocol for a population-based cohort study. BMJ Open, 2018, 8, e021727.	0.8	5
12	Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: Evidence-based clinical practice guideline. Canadian Family Physician, 2018, 64, 17-27.	0.1	94
13	Should I continue taking my acid reflux medication? Design of a pilot before/after study evaluating a patient decision aid. Canadian Pharmacists Journal, 2017, 150, 19-23.	0.4	7
14	Interventions to reduce wait times for primary care appointments: a systematic review. BMC Health Services Research, 2017, 17, 295.	0.9	89
15	Identifying approaches for assessing methodological and reporting quality of systematic reviews: a descriptive study. Systematic Reviews, 2017, 6, 117.	2.5	41
16	Promoting deceased organ and tissue donation registration in family physician waiting rooms (RegisterNow-1 trial): study protocol for a pragmatic, stepped-wedge, cluster randomized controlled registry. Trials, 2017, 18, 610.	0.7	10
17	Systematic review adherence to methodological or reporting quality. Systematic Reviews, 2017, 6, 131.	2.5	180
18	Associations Between Cardiovascular Events and Nonergot Dopamine Agonists in Parkinson's Disease. Movement Disorders Clinical Practice, 2016, 3, 257-267.	0.8	7

#	Article	IF	CITATIONS
19	Atypical antipsychotics for insomnia: a systematic review. Sleep Medicine, 2016, 22, 13-17.	0.8	72
20	The missing cause approach to unmeasured confounding in pharmacoepidemiology. Statistics in Medicine, 2016, 35, 1001-1016.	0.8	14
21	Associations between Anticholinergic Burden and Adverse Health Outcomes in Parkinson Disease. PLoS ONE, 2016, 11, e0150621.	1.1	83
22	Methodology for Developing Deprescribing Guidelines: Using Evidence and GRADE to Guide Recommendations for Deprescribing. PLoS ONE, 2016, 11, e0161248.	1.1	96
23	Assessing potentially inappropriate prescribing (PIP) and predicting patient outcomes in Ontario's older population: a population-based cohort study applying subsets of the STOPP/START and Beers' criteria in large health administrative databases. BMJ Open, 2015, 5, e010146.	0.8	19
24	Do Continuing Medical Education (CME) Events Cover the Content Physicians Want to Know? A Content Analysis of CME Offerings. Journal of Continuing Education in the Health Professions, 2015, 35, 27-37.	0.4	10
25	Trends in inpatient antiparkinson drug use in the USA, 2001–2012. European Journal of Clinical Pharmacology, 2015, 71, 1011-1019.	0.8	40
26	Potentially inappropriate prescribing (PIP) in long-term care (LTC) patients: validation of the 2014 STOPP-START and 2012 Beers criteria in a LTC population—a protocol for a cross-sectional comparison of clinical and health administrative data. BMJ Open, 2015, 5, e009715.	0.8	9
27	Do sugar-sweetened beverages cause adverse health outcomes in adults? A systematic review protocol. Systematic Reviews, 2014, 3, 108.	2.5	8
28	Do sugar-sweetened beverages cause adverse health outcomes in children? A systematic review protocol. Systematic Reviews, 2014, 3, 96.	2.5	12
29	Antibiotics for community-acquired pneumonia in adult outpatients. The Cochrane Library, 2014, 2014, CD002109.	1.5	56
30	Warfarin Treatment After Bioprosthetic Aortic Valve Replacement. JAMA - Journal of the American Medical Association, 2013, 309, 1225.	3.8	3
31	What Do Primary Care Practitioners Want to Know? A Content Analysis of Questions Asked at the Point of Care. Journal of Continuing Education in the Health Professions, 2013, 33, 224-234.	0.4	18
32	Antibiotics for community acquired pneumonia in adult outpatients., 2009,, CD002109.		25
33	Management of community acquired pneumonia. BMJ: British Medical Journal, 2007, 335, 1004-1005.	2.4	2
34	Do German General Practitioners Support Euthanasia?. European Journal of General Practice, 2005, 11, 94-100.	0.9	35
35	Antibiotics for community acquired pneumonia in adult outpatients. , 2004, , CD002109.		14
36	Reply to A. Bleyer and D.S. Alberts. Medical and Pediatric Oncology, 2003, 40, 414-414.	1.0	0

#	Article	IF	CITATIONS
37	Insert art title here:. American Journal of Medicine, 2002, 112, 157-158.	0.6	4
38	Timeless. Stroke, 2002, 33, 1743-1744.	1.0	1
39	Do statins cause cancer? A meta-analysis of large randomized clinical trials. American Journal of Medicine, 2001, 110, 716-723.	0.6	185
40	Expressing the magnitude of adverse effects in case-control studies: "the number of patients needed to be treated for one additional patient to be harmed". BMJ: British Medical Journal, 2000, 320, 503-506.	2.4	67
41	Non-ergot dopamine agonists and the risk of heart failure and other adverse cardiovascular reactions in Parkinson's disease. The Cochrane Library, 0, , .	1.5	0